Tysabri gets positive review for Crohn’s disease in US

Two FDA advisory panels recommended approving Tysabri for patients with moderate-to-severe Crohn’s disease who have failed on other drugs. Marketed by Biogen Idec and Elan, Tysabri is already approved for MS. An approval in this Crohn’s population may not boost the drug’s profits very much, but the advisory panels’ decision suggests concerns about the drug’s safety were tempered by its benefits. Tysabri has been linked to a rare viral infection of the brain (PML) and was temporarily withdrawn.

- see this release from Elan

Suggested Articles

Post-Tesaro buyout, don’t expect GlaxoSmithKline to spring for more commercial-stage oncology products anytime soon.

Already a fast-growing blockbuster, Novo Nordisk's injectable Ozempic won a major heart-helping FDA nod that could bode well for its oral sibling.

Bayer's new Vitrakvi for tumors with NTRK gene fusions is meeting skepticism in England and Germany, where cost watchdogs on Friday rejected it.